menu-iconMore mobile-close-icon
Skip Navigation
Skip Navigation
Home
Browse Guidelines
Expert Commentaries
Guideline Syntheses
Guideline Matrix
Guideline Resources
Compare Guidelines
Frequently Asked Questions
Submit Guidelines
About
myNGC
Search within:  

Sort results by:      



Filter results by:

1-20 of 120   Next >
 
2.  
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer. 2014 Apr. NGC:010348
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
3.  
Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer. 2014 Apr. NGC:010350
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
6.  
Muscle invasive and locally advanced/metastatic bladder cancer. 2011 Jan (revised 2013 Oct). NGC:010249
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
9.  
Castration-resistant prostate cancer: AUA guideline. 2013 Apr. [NGC Update Pending] NGC:009912
American Urological Association Education and Research, Inc. - Medical Specialty Society. View all guidelines by the developer(s)
10.  
Guidelines on muscle-invasive and metastatic bladder cancer. 2008 Mar (revised 2013 Mar). NGC:009826
European Association of Urology - Medical Specialty Society. View all guidelines by the developer(s)
11.  
Guidelines on renal cell carcinoma. 2000 (revised 2013 Mar). NGC:009829
European Association of Urology - Medical Specialty Society. View all guidelines by the developer(s)
12.  
Management of in-transit disease of the limbs. 2010 May (revised 2013 Feb). NGC:010259
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
13.  
Systemic therapy for unresectable stage III or metastatic cutaneous melanoma. 2012 Mar (revised 2013 Feb). NGC:010269
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
14.  
ACR Appropriateness Criteria® screening for pulmonary metastases. 1995 (revised 2013). NGC:010164
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
15.  
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma. 2012 Dec. NGC:009517
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
16.  
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. 2012 Dec. NGC:009518
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
17.  
HealthPartners Dental Group and Clinics oral cancer guideline. 2007 May 2 (revised 2012 Nov 9). NGC:009498
HealthPartners Dental Group - Professional Association. View all guidelines by the developer(s)
18.  
19.  
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. 2012 Oct. NGC:009376
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
20.  
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer. 2012 Aug. NGC:009311
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
1-20 of 120   Next >